Efficacy of Subconjunctival Injection of Bevacizumab in Regressing Corneal Neovascularisation.
To determine the efficacy of subconjunctival injection of bevacizumab in regressing corneal neovascularisation. Case series. Department of Ophthalmology, Chandka Medical College and Hospital, SMBBMU, Larkana, Pakistan, from October 2015 to March 2016. A total of 95 patients with corneal neovascularisation of more than 3 months' duration and with no history of previous or current anti-VEGF treatment were included in the study. Patients with any other active ocular disease or using any medication were excluded from the study. Subconjunctival injection of bevacizumab 0.05 ml (1.25 mg) was given near the limbus where maximum neovascularisation was seen. The final outcome was assessed after one month of injection; Pre- and post-treatment slit-lamp examination was done and corneal photograph was taken with anterior segment digital camera to see any regression in corneal neovessels from the baseline. Out of the total 95 patients, 62 (65.3%) were males and 33 (34.7%) were females, 18 (18.9%) patients were known cases of diabetes mellitus and 8 (8.4%) had hypertension. Mean age was 38.46 ±10.01 years. Mean duration of corneal neovascularisation was 1.81 ±3.68 years. After subconjunctival injection of bevacizumab, 14.7% patients showed regression in corneal neovascularisation. Subconjunctival injection of bevacizumab is a promising modality for treatment of corneal neovascularisation and may be used in adjunct to other therapies.